Erythema Multiforme Major in a Dog Treated with Intravenous Human Immunoglobulin and Immunosuppressive Therapy.

J Am Anim Hosp Assoc

From the Department of Veterinary Clinical Sciences (S.J.R., V.M.B., M.C.W.), and Department of Pathobiological Sciences (I.M.L.), School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana.

Published: November 2020

Download full-text PDF

Source
http://dx.doi.org/10.5326/JAAHA-MS-6896DOI Listing

Publication Analysis

Top Keywords

erythema multiforme
4
multiforme major
4
major dog
4
dog treated
4
treated intravenous
4
intravenous human
4
human immunoglobulin
4
immunoglobulin immunosuppressive
4
immunosuppressive therapy
4
erythema
1

Similar Publications

Perforating ENL: A variant of type 2 lepra reaction.

J Clin Tuberc Other Mycobact Dis

February 2025

Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.

Lepra reactions are acute episodic inflammatory reactions that occur during illness due to abrupt changes in the body's immunological response against Mycobacterium leprae. These are of two types, type 1 and type 2. Type 2 reaction is also called Erythema Nodosum Leprosum (ENL).

View Article and Find Full Text PDF

Traditionally, dermatological education emphasizes hair, skin and nails in its curriculum. There is a practice gap with regard to knowledge of normal oral mucosa variants, performance of the oral examination, and competence in diagnosing and treating oral mucosal disorders. The oral mucosa falls within the purview of dermatology.

View Article and Find Full Text PDF

Immunotherapy, particularly that based on blocking checkpoint proteins in many tumors, including melanoma, Merkel cell carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast (TNB cancer), renal cancer, and gastrointestinal and endometrial neoplasms, is a therapeutic alternative to chemotherapy. Immune checkpoint inhibitor (ICI)-based therapies have the potential to target different pathways leading to the destruction of cancer cells. Although ICIs are an effective treatment strategy for patients with highly immune-infiltrated cancers, the development of different adverse effects including cutaneous adverse effects during and after the treatment with ICIs is common.

View Article and Find Full Text PDF

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous disorders characterized by extensive tissue necrosis; they are often accompanied by severe ocular complications (SOC). The regulatory role of microRNAs (miRNAs) in modulating immune responses in SJS/TEN is not fully understood, particularly in relation to chronic SOC. We explored the expression profiles of specific miRNAs and their potential impact on the regulation of key innate immune genes in patients with SJS/TEN with SOC.

View Article and Find Full Text PDF

Stevens-Johnson induced by imiquimod 5% cream: a case report.

Dermatol Reports

November 2024

Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.

Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!